Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
D000067956:Adenylyl Cyclase Inhibitors; D000661:Amphetamine / Q000009:adverse effects; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001923:Brain Chemistry; D002415:Cats; D003342:Corpus Striatum / Q000503:physiopathology; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D018492:Dopamine Antagonists; D006801:Humans; D008032:Limbic System / Q000503:physiopathology; D011605:Psychoses, Substance-Induced / Q000503:physiopathology; D011618:Psychotic Disorders / Q000378:metabolism / Q000503:physiopathology*; D011817:Rabbits; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D012559:Schizophrenia / Q000503:physiopathology; D013569:Synapses / Q000378:metabolism; D014149:Tranquilizing Agents / Q000494:pharmacology*
D000067956:Adenylyl Cyclase Inhibitors; D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D014149:Tranquilizing Agents; D000661:Amphetamine; D004298:Dopamine